ZFYVE9
Summary: This gene encodes a double zinc finger motif-containing protein that participates in the transforming growth factor-beta (TGFB) signalling pathway. The encoded protein interacts directly with SMAD2 and SMAD3, and recruits SMAD2 to the TGFB receptor. There are multiple pseudogenes for this gene on chromosomes 2, 15, and X. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2013].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| zinc finger FYVE-type containing 9 | MIM:603755 | Ensembl:ENSG00000157077 | HGNC:HGNC:6775 | PA30532 | 1p32.3 |
Gene Categories:
PROTEASEGO terms in ZFYVE9
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IPI | GO:0005515 | protein binding |
| MF | IDA | GO:0005545 | 1-phosphatidylinositol binding |
| MF | NAS | GO:0008236 | serine-type peptidase activity |
| MF | IPI | GO:0019904 | protein domain specific binding |
| MF | IEA | GO:0046872 | metal ion binding |
| CC | IBA | GO:0005769 | early endosome |
| CC | NAS | GO:0005769 | early endosome |
| CC | IDA | GO:0005829 | cytosol |
| CC | IDA | GO:0031901 | early endosome membrane |
| CC | TAS | GO:0031901 | early endosome membrane |
| CC | IMP | GO:0032991 | protein-containing complex |
| CC | IDA | GO:0043231 | intracellular membrane-bounded organelle |
| BP | IEA | GO:0006508 | proteolysis |
| BP | IBA | GO:0006886 | intracellular protein transport |
| BP | NAS | GO:0006897 | endocytosis |
| BP | IMP | GO:0007179 | transforming growth factor beta receptor signaling pathway |
| BP | NAS | GO:0007179 | transforming growth factor beta receptor signaling pathway |
| BP | TAS | GO:0007179 | transforming growth factor beta receptor signaling pathway |
| BP | IBA | GO:0015031 | protein transport |
| BP | IBA | GO:0016197 | endosomal transport |
Gene expression in normal tissue: ZFYVE9
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in ZFYVE9
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| pid | tgfbrpathway | TGF-beta receptor signaling |
| netpath | Pathway_TGF_beta_Receptor | TGF_beta_Receptor |
| kegg | hsa04144 | Endocytosis - Homo sapiens (human) |
| kegg | hsa04350 | TGF-beta signaling pathway - Homo sapiens (human) |
| wikipathways | WP366 | TGF-beta Signaling Pathway |
| wikipathways | WP560 | TGF-beta Receptor Signaling |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-170834 | Signaling by TGF-beta Receptor Complex |
| reactome | R-HSA-170834 | Signaling by TGF-beta Receptor Complex |
| reactome | R-HSA-2173788 | Downregulation of TGF-beta receptor signaling |
| reactome | R-HSA-2173789 | TGF-beta receptor signaling activates SMADs |
| reactome | R-HSA-2173789 | TGF-beta receptor signaling activates SMADs |
| reactome | R-HSA-3304349 | Loss of Function of SMAD2/3 in Cancer |
| reactome | R-HSA-3304351 | Signaling by TGF-beta Receptor Complex in Cancer |
| reactome | R-HSA-3304356 | SMAD2/3 Phosphorylation Motif Mutants in Cancer |
| reactome | R-HSA-3315487 | SMAD2/3 MH2 Domain Mutants in Cancer |
| reactome | R-HSA-3656532 | TGFBR1 KD Mutants in Cancer |
| reactome | R-HSA-3656534 | Loss of Function of TGFBR1 in Cancer |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-9006936 | Signaling by TGF-beta family members |
| reactome | R-HSA-9006936 | Signaling by TGF-beta family members |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD213 | SMR000068650 | 4 |
| iGMDRD105 | Triptolide | 3 |
| iGMDRD289 | Parthenolide | 3 |
| iGMDRD434 | BMS-536924 | 1 |
| iGMDRD5 | Tyrphostin AG 1478 | 1 |
| iGMDRD121 | GMX1778 | 3 |
| iGMDRD82 | Quiflapon | 3 |
| iGMDRD322 | FK 866 | 4 |
| iGMDRD505 | Pevonedistat | 4 |
| iGMDRD147 | Prima-1 | 4 |
| iGMDRD286 | Nsc 632839 | 7 |
| iGMDRD872 | BRD7137 | 1 |
| iGMDRD150 | RITA | 7 |
| iGMDRD522 | ML-030 | 1 |
| iGMDRD148 | Pifithrin-mu | 3 |
| iGMDRD248 | BRD4354 | 1 |
| iGMDRD84 | Lovastatin acid | 3 |
| iGMDRD307 | Manumycin A | 3 |
| iGMDRD945 | ML214 | 3 |
| iGMDRD211 | (1S,3R)-RSL3 | 3 |
| iGMDRD177 | Teniposide | 3 |
| iGMDRD314 | Tanespimycin | 2 |
| iGMDRD57 | Chloropentafluorobenzene | 3 |
| iGMDRD341 | Triacsin c | 2 |
| iGMDRD85 | Ursolic acid | 4 |
| iGMDRD441 | TW 37 | 3 |
| iGMDRD885 | Compound 110 | 3 |
| iGMDRD318 | PAC-1 | 3 |
| iGMDRD801 | 2,4-dideoxy-DC-45-A2 | 5 |
| iGMDRD294 | Batimastat | 3 |
| iGMDRD782 | DC-45-A2 | 3 |
| iGMDRD171 | Pemetrexed | 3 |
| iGMDRD268 | Cerulenin | 6 |
| iGMDRD524 | ISX-9 | 1 |
| iGMDRD690 | PRIMA-1MET | 3 |
| iGMDRD60 | Quinoclamine | 1 |
| iGMDRD640 | CAY10618 | 3 |
| iGMDRD224 | Necrostatin-1 | 4 |
| iGMDRD888 | Compound 44 | 3 |
| iGMDRD562 | Navitoclax | 3 |
| iGMDRD100 | Zebularine | 3 |
| iGMDRD188 | Piperlongumine | 5 |
| iGMDRD779 | PRL-3 Inhibitor I | 1 |
| iGMDRD427 | ABT737 | 3 |
| iGMDRD144 | NSC95397 | 3 |
| iGMDRD670 | ML 210 | 5 |
| iGMDRD772 | BRD4770 | 6 |
| iGMDRD634 | SCHEMBL2608041 | 8 |
| iGMDRD61 | Kinetin riboside | 1 |
| iGMDRD797 | ISOX DUAL | 3 |
| iGMDRD201 | SKI II | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in ZFYVE9
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.